Guggenheim Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $12

Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $12.